✦ LIBER ✦

Safety and immunogenicity of new cell-cultured smallpox vaccine compared with calf-lymph derived vaccine: a blind, single-centre, randomised controlled trial

✍ Scribed by Richard N Greenberg; Jeffrey S Kennedy; David J Clanton; Elizabeth A Plummer; Lynda Hague; John Cruz; Francis A Ennis; William C Blackwelder; Robert J Hopkins

Book ID: 117287744
Publisher: The Lancet
Year: 2005
Tongue: English
Weight: 243 KB
Volume: 365
Category: Article
ISSN: 0140-6736
DOI: 10.1016/s0140-6736(05)17827-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Efficacy, safety, and immunogenicity of

Efficacy, safety, and immunogenicity of a Vero-cell-culture-derived trivalent influenza vaccine: a multicentre, double-blind, randomised, placebo-controlled trial

✍ P Noel Barrett; Gregory Berezuk; Sandor Fritsch; Gerald Aichinger; Mary Kate Har 📂 Article 📅 2011 🏛 The Lancet 🌐 English ⚖ 209 KB

A randomized, double-blind, controlled c

A randomized, double-blind, controlled clinical trial to evaluate the efficacy and safety of CJ-50300, a newly developed cell culture-derived smallpox vaccine, in healthy volunteers

✍ Hee-Chang Jang; Choong Jong Kim; Kye Hyoung Kim; Kwang-Hee Lee; Young-Ho Byun; B 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 204 KB

Safety and immunogenicity of concomitant

Safety and immunogenicity of concomitant vaccination with the cell-culture based Japanese Encephalitis vaccine IC51 and the hepatitis A vaccine HAVRIX®1440 in healthy subjects: A single-blind, randomized, controlled Phase 3 study

✍ A. Kaltenböck; K. Dubischar-Kastner; G. Eder; W. Jilg; C. Klade; H. Kollaritsch; 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 278 KB

A randomised, single-blind, dose-range s

A randomised, single-blind, dose-range study to assess the immunogenicity and safety of a cell-culture-derived A/H1N1 influenza vaccine in adult and elderly populations

✍ Christoph Hatz; Jakob P. Cramer; André Vertruyen; Tino F. Schwarz; Frank von Son 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 376 KB

Immunogenicity and safety of fully liqui

Immunogenicity and safety of fully liquid DTaP5-IPV-Hib compared with DTaP3-IPV/Hib when both coadministered with a heptavalent pneumococcal conjugate vaccine (PCV7) at 2, 3, 4, and 12 to 18 months of age: A phase III, single-blind, randomised, controlled, multicentre study

✍ Emmanuel Grimprel; Jacek Wysocki; Florence Boisnard; Stéphane Thomas; Grace Mwaw 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 338 KB